注射用黄芪多糖辅助原发性肝癌化疗的应用及安全性研究

doi:10.3760/cma.j.issn.1007-1245.2023.17.017

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (17): 2442-2445.DOI: 10.3760/cma.j.issn.1007-1245.2023.17.017

注射用黄芪多糖辅助原发性肝癌化疗的应用及安全性研究

刘运慧杨秋敏林春丽郝蕊

商丘市第一人民医院肿瘤二科，商丘　476000

收稿日期:2023-03-14 出版日期:2023-09-01 发布日期:2023-09-21
通讯作者: 刘运慧，Email：liuyunhuire@126.com
基金资助:
河南省医学科技攻关项目（LHGJ20210021132）

Application and safety study of astragalus polysaccharides for injection assisted chemotherapy for primary liver cancer

Liu Yunhui, Yang Qiumin, Lin Chunli, Hao Rui

Second Department of Oncology, Shangqiu First People's Hospital, Shangqiu 476000, China

Received:2023-03-14 Online:2023-09-01 Published:2023-09-21
Contact: Liu Yunhui, Email: liuyunhuire@126.com
Supported by:
Medical Science and Technology Research Project of Henan Province (LHGJ20210021132)

摘要/Abstract

摘要：

目的　观察注射用黄芪多糖在原发性肝癌含奥沙利铂化疗方案中的应用及对骨髓抑制的防治效果。方法　本文为随机对照试验。选取2020年1月至2021年10月期间在商丘市第一人民医院接受化疗的120例原发性肝癌患者为研究对象，通过抽签法对患者进行随机分组，每组60例。对照组男40例，女20例，年龄（50.33±1.26）岁，予以含奥沙利铂化疗方案；观察组男38例，女22例，年龄（51.42±1.35）岁，在对照组化疗基础上采用注射用黄芪多糖配合治疗。比较两组患者化疗情况及外周血象指标变化情况；对所有患者开展为期1年的随访，比较两组患者化疗后骨髓抑制的发生情况、毒性反应分度。采用χ²检验、t检验。结果　治疗后，观察组的疾病控制率高于对照组［83.33%（50/60）比58.33%（35/60）］，1个月内化疗定时、定量完成率高于对照组［93.33%（56/60）比75.00%（45/60）］，差异均有统计学意义（χ²=9.076、9.190；均P<0.05）；治疗后，观察组的白细胞计数高于对照组［（6.25±2.44）×10⁹/L比（4.39±1.33）×10⁹/L］，中性粒细胞百分比高于对照组［（53.34±8.31）%比（48.45±5.42）%］，T淋巴细胞亚群CD3+CD4+高于对照组［（29.11±8.43）%比（25.42±5.36）%］、CD3+CD8+低于对照组［（25.45±5.44）%比（28.76±5.16）%］，差异均有统计学意义（t=5.185、3.818、2.861、3.420；均P<0.05）；随访期间，观察组的骨髓抑制总发生率低于对照组［25.00%（15/60）比46.67%（28/60）］，差异有统计学意义（χ²=6.125，P<0.05）。结论　注射用黄芪多糖配合含奥沙利铂化疗对改善原发性肝癌患者外周血象指标、降低骨髓抑制发生率均有积极意义。

关键词:

原发性肝癌, 奥沙利铂, 注射用黄芪多糖, 骨髓抑制

Abstract:

Objective　To observe the application of astragalus polysaccharides for injection in oxaliplatin chemotherapy regimen for primary liver cancer and its preventive and therapeutic effects on bone marrow depression. Methods　This was a randomized controlled trial. A total of 120 patients with primary liver cancer who received chemotherapy in Shangqiu First People's Hospital from January 2020 to October 2021 were selected as the research objects, and were divided into two groups by drawing lots. In the control group, 40 males and 20 females, aged (50.33±1.26) years, were treated with oxaliplatin chemotherapy regimen. In the observation group, 38 males and 22 females, aged (51.42±1.35) years, were treated with astragalus polysaccharides for injection on the basis of chemotherapy regimen in the control group. The chemotherapy and changes of peripheral hemogram indexes were compared between the two groups. All the patients were followed up for 1 year to compare the occurrence of bone marrow depression and the degree of toxic reaction after chemotherapy between the two groups. χ² test and t test were used. Results　After treatment, the disease control rate of the observation group was higher than that of the control group [83.33% (50/60) vs. 58.33% (35/60)], and the timed and quantitative completion rate of chemotherapy within 1 month was higher than that of the control group [93.33% (56/60) vs. 75.00% (45/60)], with statistically significant differences (χ²=9.076 and 9.190, both P<0.05). After treatment, the white blood cell count in the observation group was higher than that in the control group [(6.25±2.44) ×10⁹/L vs. (4.39±1.33) ×10⁹/L], the percentage of neutrophils was higher than that in the control group [(53.34±8.31)% vs. (48.45±5.42)%], the T lymphocyte subsets CD3+CD4+ was higher than that in the control group [(29.11±8.43)% vs. (25.42±5.36)%], and the CD3+CD8+ was lower than that in the control group [(25.45±5.44)% vs. (28.76±5.16)%], with statistically significant differences (t=5.185, 3.818, 2.861, and 3.420; all P<0.05). During the follow-up period, the incidence of bone marrow suppression in the observation group was lower than that in the control group [25.00% (15/60) vs. 46.67% (28/60)], with a statistically significant difference (χ²=6.125, P<0.05). Conclusion　Astragalus polysaccharides for injection combined with oxaliplatin chemotherapy regimen has positive significance in improving the peripheral hemogram indexes and reducing the incidence of bone marrow depression in patients with primary liver cancer.

Key words:

Primary liver cancer, Oxaliplatin, Astragalus polysaccharides for injection, Bone marrow depression

刘运慧杨秋敏林春丽郝蕊.

注射用黄芪多糖辅助原发性肝癌化疗的应用及安全性研究 [J]. 国际医药卫生导报, 2023, 29(17): 2442-2445.

Liu Yunhui, Yang Qiumin, Lin Chunli, Hao Rui.

Application and safety study of astragalus polysaccharides for injection assisted chemotherapy for primary liver cancer [J]. International Medicine and Health Guidance News, 2023, 29(17): 2442-2445.

参考文献

[1] 陈锡莲,杨勇卫,林静,等. HBV相关原发性肝癌患者T淋巴细胞亚群和细胞因子表达水平差异研究[J]. 国际医药卫生导报,2021,27(19):2980-2984. DOI:10.3760/cma.j.issn.1007-1245.2021.19.005.
[2] Yin T, Nie L, Wu D, et al. Chemotherapy for breast cancer progresses to liver metastases after surgery and systemic treatment[J]. Transl Cancer Res, 2020, 9(2): 993-1000. DOI: 10.21037/tcr.2019.12.59.
[3] 陈琰,陈坚,张建华. 聚乙二醇化重组人粒细胞集落刺激因子在恶性肿瘤化疗后骨髓抑制患者中的应用[J]. 实用临床医药杂志,2019,23(23):61-63. DOI:10.7619/jcmp. 201923018.
[4] 于红,王维涛,嵇钧安,等. 芪胶升白胶囊联合粒细胞集落刺激因子治疗癌症化疗后骨髓抑制疗效观察[J]. 现代中西医结合杂志,2019,28(6):621-623. DOI:10.3969/j.issn.1008- 8849.2019.06.014.
[5] 崔运浩,初杰,范颖,等. 当归多糖、黄芪多糖及其配伍对化疗性骨髓抑制小鼠骨髓干细胞的转录因子GATA1、BCL11A、KLF1、NFE2影响[J]. 中华中医药学刊,2019,37(11):2796-2801. DOI:10.13193/j.issn.1673-7717. 2019.11.059.
[6] 史志红,周晓,班志芬. 幽门螺杆菌感染与肝癌分期、细胞分化和病理组织类型的相关性分析[J]. 实用肿瘤杂志,2018,33(2):162-164.
[7] 李民,熊俊. «原发性肝癌诊疗规范(2017年版)»解读[J]. 中国普通外科杂志,2019,28(7):785-789. DOI:10.7659/j.issn.1005-6947.2019.07.003.
[8] Mercier F, Djebli N, González-Sales M, et al. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors[J]. Cancer Chemother Pharmacol, 2022, 89(3): 363-372. DOI: 10.1007/s00280-022-04402-w.
[9] Boccia R, Glaspy J, Crawford J, et al. Chemotherapy-induced neutropenia and febrile neutropenia in the us: a beast of burden that needs to be tamed[J]. Oncologist, 2022, 27(8): 625-636. DOI: 10.1093/oncolo/oyac074.
[10] 鲜林峰,方乐天,刘文斌,等. 原发性肝癌流行现状、主要发病机制及防控策略[J]. 中国癌症防治杂志,2022,14(3):320-328. DOI:10.3969/j.issn.1674-5671.2022.03.13.
[11] 张栋华,周晓鲁,魏涛. 奥沙利铂联合表柔比星经导管动脉栓塞化疗治疗原发性肝癌的临床疗效[J]. 癌症进展,2022,20(9):959-961. DOI:10.11877/j.issn.1672-1535.2022.20. 09.24.
[12] 魏涛. 含奥沙利铂化疗方案用于治疗原发性肝癌的临床疗效及对患者免疫功能及肿瘤标志物的影响[J]. 实用癌症杂志,2021,36(9):1463-1466. DOI:10.3969/j.issn.1001- 5930.2021.09.018.
[13] 刘海英,陈峰,吴宁. 肝癌TACE术后败血症与骨髓抑制相关性分析[J]. 介入放射学杂志,2020,29(10):1033-1035. DOI:10.3969/j.issn.1008-794X.2020.10.016.
[14] 孔惠敏,苏伟青,叶红,等.当归补血汤及其主要成分对骨髓抑制小鼠的抗造血细胞凋亡的研究[J].中国实验血液学杂志,2022,30(6):1679-1687.DOI:10.19746/j.cnki.issn1009- 2137.2022.06.009.
[15] 熊宏泰,高劲,于惠博,等. 近20年中医药防治化疗后骨髓抑制研究现状可视化分析[J]. 中国中医药信息杂志,2023,30(3):31-37. DOI:10.19879/j.cnki.1005-5304.202203729.
[16] 王燕国,陈文群,徐寒松,等. 黄芪多糖对2型糖尿病外周血内皮祖细胞归巢干预作用[J]. 中医药临床杂志,2020,32(6):1088-1094. DOI:10.16448/j.cjtcm.2020.0626.
[17] 李秀,初杰,李影迪,等. 当归/黄芪多糖对腹腔注射环磷酰胺小鼠骨髓造血影响随机平行对照研究[J]. 实用中医内科杂志,2017,31(5):52-58. DOI:10.13729/j.issn.1671- 7813. 2017.05.19.
[18] 席雪琴,何愉胜. 黄芪多糖在人血γδT细胞体外抑制人肺癌A549细胞增殖作用的研究[J]. 中国免疫学杂志,2020,36(8):944-947. DOI:10.3969/j.issn.1000- 484X.2020.08.010.

注射用黄芪多糖辅助原发性肝癌化疗的应用及安全性研究

Application and safety study of astragalus polysaccharides for injection assisted chemotherapy for primary liver cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics